Immunotherapy may lead to long-term remission of metastatic breast cancer
https://www.facingourrisk.org/XRAY/immunotherapy-remission-metastatic-breast-cancer
Full article: https://doi.org/10.1038/s41591-018-0040-8
Metastatic breast cancer is often difficult to treat. In a new approach, called adoptive cell therapy (ACT), a patient’s own T-cells (a type of cancer-fighting immune cells) are collected, multiplied in a lab, and then returned to the patient. The goal is to enhance the patient’s immune system with many more T-cells that recognize and attack metastasized tumor cells. This study reports on a single patient whose metastatic breast cancer is still in remission (no evidence of disease) after more than 22 months following ACT. (8/16/18)
Questions To Ask Your Health Care Provider
- What is the best treatment approach for my type of cancer?
- Am I eligible for the clinical trial covered in this review?
- Am I eligible for any other clinical trials?
- should I have my tumor tested for biomarkers?
- What are the risks and potential benefits of participating in a clinical trial?
Open Clinical Trials
You can search for clinical trials for people with HR-positive or ER-positive metastatic breast cancer here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.